63659-19-8

Usage

Uses

Used in Pharmaceutical Industry:
Betaxolol hydrochloride is used as an antihypertensive agent for the treatment of mild to moderate hypertension. It is effective due to its cardioselective β1-adrenergic blocking properties, which help lower blood pressure with once-daily dosing.
Used in Ophthalmology:
Betaxolol hydrochloride is used as an antiglaucoma agent, being evaluated for its potential in treating glaucoma by reducing intraocular pressure.
Used in Sports Performance Enhancement:
Betaxolol hydrochloride is used as a performance-enhancing substance in sports, where formulations containing β-adrenergic receptor antagonists are utilized to improve physical performance in athletes.
Used in Analytical and Forensic Applications:
Betaxolol hydrochloride is used as an analytical reference standard for forensic applications, serving as a research tool in various analytical processes.
Used in Antifungal Applications:
Betaxolol hydrochloride is also used in antifungal applications, indicating its potential to combat fungal infections.

Originator

Synthelabo (France)

Biological Activity

Selective β 1 -adrenoceptor antagonist.

InChI:InChI=1/C18H29NO3.ClH/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16;/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3;1H

Upstream product

• 63659-18-7 betaxolol 

Downstream Products

• 101623-77-2 1--N-isopropylamino>-3--2-propanol 
• 125720-87-8 1-[4-(2-Cyclopropylmethoxy-ethyl)-phenoxy]-3-isopropylamino-propan-2-one oxime 
• 125720-88-9 1-[4-(2-Cyclopropylmethoxy-ethyl)-phenoxy]-3-isopropylamino-propan-2-one oxime 
• 125721-11-1 3-[4-(2-Cyclopropylmethoxy-ethyl)-phenoxy]-2-[(Z)-hydroxyimino]-propionaldehyde oxime 
• 125721-02-0 3-[4-(2-Cyclopropylmethoxy-ethyl)-phenoxy]-2-[(E)-hydroxyimino]-propionaldehyde oxime 
• 63659-18-7 betaxolol 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING SALT SENSITIVITY OF BLOOD PRESSURE

To characterize the urinary exosome miRNome, microarrays were used to identify the miRNA spectrum present within urinary exosomes from ten individuals that were previously classified for their salt sensitivity status. The present application discloses distinct patterns of selected exosomal miRNA expression that were different between salt-sensitive (SS), salt-resistant (SR), and inverse salt-sensitive (ISS) individuals. These miRNAs can be useful as biomarkers either individually or as panels comprising multiple miRNAs. The present invention provides compositions and methods for identifying, diagnosing, monitoring, and treating subjects with salt sensitivity of blood pressure. The applications discloses panels of miRNAs useful for comparing profiles, and in some cases one or more of the miRNAs in a panel can be used. The miRNAs useful for distinguishing SS and SR or ISS and SR subjects. One or more of the 45 miRNAs can be used. Some of the miRNAs have not been previously reported to be circulating. See those miRNAs with asterisks in FIG. 1 and below. The present invention encompasses the use of one or more of these markers for identifying and diagnosing SR, SS, and ISS subjects.

PROCESS FOR PREPARATION OF PHENOXYPROPANOL AMINES

The present invention describes an improved method for the preparation of l-[4-{2- (cyclopropylmethoxy)ethyl}phenoxy]-3-[(1-methylethyl)amino]-2-propanol of Formula-(I) and its pharmaceutically acceptable salt, which comprises reacting 4 - [ 2 — (Cyclopropylmethoxy) ethyl] phenol with epichlorohydrin in presence of mild base and polar protic solvent to isolate 1 - {4 - [2 - (cyclopropylmethoxy)ethyl] - phenoxy} - 2, 3 - epoxy propane, which is further reacted with isopropyl amine to get betaxolol formula (I).

Process for the selective alkylation of betaxolol intermediates

The present invention relates to a process for the selective alkylation of intermediates of betaxolol.